3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
272
Lymphoma, Large B-Cell, Diffuse
259
Leukemia, Lymphocytic, Chronic, B-Cell
189
Lymphoma, Non-Hodgkin
187
Lymphoma, Mantle-Cell
165
Lymphoma, Follicular
164
Lymphoma, B-Cell, Marginal Zone
115
Leukemia
94
Burkitt Lymphoma
82
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Waldenstrom Macroglobulinemia
77
Lymphoma, B-Cell
62
Recurrence
51
Hodgkin Disease
50
Lymphoma, Large-Cell, Immunoblastic
44
Lymphoma, Large-Cell, Anaplastic
20
Leukemia, Myeloid, Acute
20
Myelodysplastic Syndromes
18
Intraocular Lymphoma
15
Hematologic Neoplasms
15
Neoplasms
14
Dendritic Cell Sarcoma, Interdigitating
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Multiple Myeloma
13
Leukemia, Hairy Cell
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Neoplasms, Plasma Cell
10
Leukemia, Prolymphocytic
10
Lymphoma, T-Cell
9
Leukemia, Myelomonocytic, Chronic
9
Interventions
ofatumumab
1
daratumumab
1
Transcranial Direct Current Stimulation
1
Salpingo-oophorectomy
1
Rituximab
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
Rituximab
×
Clear all
NCT03274375
2023-07-13
IANMDAR
Assistance Publique - Hôpitaux de Paris
Phase 2
Recruiting
20 enrolled